Role of Biomarkers in Cancer Diagnosis and Therapeutics
- 1st Edition - May 1, 2026
- Latest edition
- Editors: Sushama Talegaonkar, Lalit Kumar, Dalapathi Gugulothu
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 4 4 0 4 1 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 4 4 0 4 2 - 7
Role of Biomarkers in Cancer Diagnosis and Therapeutics offers a thorough exploration of the critical roles biomarkers play in cancer detection, diagnosis, monitoring, and therap… Read more
Purchase options
Role of Biomarkers in Cancer Diagnosis and Therapeutics offers a thorough exploration of the critical roles biomarkers play in cancer detection, diagnosis, monitoring, and therapy. The book is divided into three parts: the first focuses on established and emerging biomarkers like PSA and CEA, detailing their biochemical characteristics and clinical relevance. The second section examines metabolic pathways utilized by cancer cells, highlighting key enzymes and their therapeutic potential. The final part discusses innovative strategies targeting cell cycle checkpoints and DNA repair mechanisms, including synthetic lethality through PARP inhibitors. This essential resource provides researchers and clinicians with insights into novel metabolic targets and cutting-edge treatment strategies. By addressing current applications and future challenges, including the integration of AI and multi-omics approaches, the book equips readers with actionable knowledge to advance personalized cancer care and navigate the dynamic landscape of oncology.
- Provides an in-depth analysis of both established and emerging cancer biomarkers, detailing their biochemical characteristics, clinical relevance, and diagnostic potential across various malignancies
- Explores critical metabolic pathways utilized by cancer cells, highlighting key enzymes and their therapeutic implications, thereby offering insights into novel targets for cancer treatment
- Discusses cutting-edge approaches that target cell cycle checkpoints and DNA repair mechanisms, including the concept of synthetic lethality, equipping readers with advanced knowledge for personalized cancer therapies
Scientists and researchers in the fields of oncology, molecular biology, and biochemistry who are studying cancer biomarkers and their applications in diagnosis and treatment
I. Biomarkers in Cancer Diagnosis and Treatment
1. Prostate-Specific Antigen (PSA)
2. Carcinoembryonic Antigen (CEA)
3. Tissue Polypeptide-Specific Antigen (TPS) CA72-4
4. Carbohydrate Antigen 19-9 (CA19-9)
5. Carbohydrate Antigen 125 (CA-125)
6. Carbohydrate Antigen 72-4 (CA72-4)
7. Aminopeptidase N
8. Alkaline Phosphatase
9. CD26/Dipeptidyl Peptidase (DPP)4
10. Genetic Biomarkers in Cancer
11. Immunology Biomarkers in Cancer
12. Microbiome Biomarkers in Cancer
13. Glycobiology Biomarkers in Cancer
14. Epigenetic Biomarkers in Cancer
II. Metabolic Targets and Cancer Therapeutics
15. Introduction to Metabolic Targets and Autophagy
16. Glucose Metabolism – Hexokinase-2 (HK2), Lactate Dehydrogenase A (LDHA), Pyruvate Kinase M2 Isoform (PKM2), Pyruvate Dehydrogenase (PDK), Glucose Transporter, Enolase 1 (ENO1), and Monocarboxylate Transporter (MCT1)
17. Nucleic Acid Metabolism – Folate Cycle, Nucleotide Incorporation (DNA Polymerase/Ribonucleotide Reductase (RNR)), Deoxynucleotide Synthesis (RNR), and Thymidine Synthesis (TYMS)
18. Amino Acid Metabolism – Arginine and Asparagine, Serine/Threonine Protein Kinase (Glycogen Synthase Kinase-3 (GSK-3))
19. Glucose and Amino Acid Metabolism - Isocitrate Dehydrogenase-1 (IDH-1)
20. Glucose, Nucleic Acid, Fatty Acid, and Amino Acid Metabolism – Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
III. Miscellaneous Cancer Therapeutic Approaches
21. Targeting DNA Repair Pathways – O-6-Methylguanine-DNA Methyltransferase (MGMT), Base Excision Repair, Double Strand Breaks Repair, and mtDNA Repair
22. Cell Cycle Inhibition – Cyclin-Dependent Kinases (CDKs), and G1 Checkpoint
23. Topoisomerase-Induced DNA Damage and Therapeutic Potential
24. Polo-like Kinase 4 (PLK4) Inhibitors in Cancer Therapy
25. Synthetic Lethality by Poly (ADP-Ribose) Polymerase Inhibitors
26. Innovative Therapeutic Approaches
1. Prostate-Specific Antigen (PSA)
2. Carcinoembryonic Antigen (CEA)
3. Tissue Polypeptide-Specific Antigen (TPS) CA72-4
4. Carbohydrate Antigen 19-9 (CA19-9)
5. Carbohydrate Antigen 125 (CA-125)
6. Carbohydrate Antigen 72-4 (CA72-4)
7. Aminopeptidase N
8. Alkaline Phosphatase
9. CD26/Dipeptidyl Peptidase (DPP)4
10. Genetic Biomarkers in Cancer
11. Immunology Biomarkers in Cancer
12. Microbiome Biomarkers in Cancer
13. Glycobiology Biomarkers in Cancer
14. Epigenetic Biomarkers in Cancer
II. Metabolic Targets and Cancer Therapeutics
15. Introduction to Metabolic Targets and Autophagy
16. Glucose Metabolism – Hexokinase-2 (HK2), Lactate Dehydrogenase A (LDHA), Pyruvate Kinase M2 Isoform (PKM2), Pyruvate Dehydrogenase (PDK), Glucose Transporter, Enolase 1 (ENO1), and Monocarboxylate Transporter (MCT1)
17. Nucleic Acid Metabolism – Folate Cycle, Nucleotide Incorporation (DNA Polymerase/Ribonucleotide Reductase (RNR)), Deoxynucleotide Synthesis (RNR), and Thymidine Synthesis (TYMS)
18. Amino Acid Metabolism – Arginine and Asparagine, Serine/Threonine Protein Kinase (Glycogen Synthase Kinase-3 (GSK-3))
19. Glucose and Amino Acid Metabolism - Isocitrate Dehydrogenase-1 (IDH-1)
20. Glucose, Nucleic Acid, Fatty Acid, and Amino Acid Metabolism – Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
III. Miscellaneous Cancer Therapeutic Approaches
21. Targeting DNA Repair Pathways – O-6-Methylguanine-DNA Methyltransferase (MGMT), Base Excision Repair, Double Strand Breaks Repair, and mtDNA Repair
22. Cell Cycle Inhibition – Cyclin-Dependent Kinases (CDKs), and G1 Checkpoint
23. Topoisomerase-Induced DNA Damage and Therapeutic Potential
24. Polo-like Kinase 4 (PLK4) Inhibitors in Cancer Therapy
25. Synthetic Lethality by Poly (ADP-Ribose) Polymerase Inhibitors
26. Innovative Therapeutic Approaches
- Edition: 1
- Latest edition
- Published: May 1, 2026
- Language: English
ST
Sushama Talegaonkar
Dr. Sushama Talegaonkar is an Associate Professor at the Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, India. She has approximately 21 years of experience, and has published more than 220 research papers in high impact international journals. Besides this, she has coauthored 6 books and authored 15 chapters in international reference books. Recently, she received the Professor C. J. Shishoo Award for Best Research. Her research paper titled “Development and bioavailability assessment of ramipril nanoemulsion formulation” has received the most cited research paper award on behalf of Elsevier and the board of European Journal of Pharmaceutics and Biopharmaceutics. She was awarded the prestigious Motan Devi Dandiya Biennial Prize for best publication in Pharmaceutical Sciences for the period 2010–11. Dr. Talegaonkar is actively involved in developing a wide variety of smart and functionalized nanodrug delivery systems for targeted anticancer drug delivery.
Affiliations and expertise
Associate Professor, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, IndiaLK
Lalit Kumar
Lalit Kumar is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, India. His area of research includes the development of nanocarriers for drug-targeting tumor cells in the colon, brain, breast, and lungs.
Affiliations and expertise
Assistant Professor, Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, IndiaDG
Dalapathi Gugulothu
Dr. Dalapathi Gugulothu working as Assistant professor, Department of Pharmaceutics , Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University , New Delhi.
Affiliations and expertise
Delhi Institute of Pharmaceutical Sciences and Research, India